Following the FDA’s clearance earlier this year of its large-bore catheter for removing oxygen-blocking blood clots, ...

This performance was driven by strong demand in cardiopulmonary products, particularly the Essenz Perfusion System, and modest growth in neuromodulation across Europe and other global markets.

We came across a bullish thesis on TransMedics Group, Inc. (TMDX) on Substack by Oliver | MMMT Wealth. In this article, we ...

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the ...

The Andover, Massachusetts–based medtech company, which offers an organ care system (OCS) for transplant therapy, hit $143.5 ...

Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance ...

More than half a century after the world’s first heart transplant, scientists are finding fascinating ways to improve the ...

TransMedics Group, Inc.’s TMDX share price has surged by 21.55%, which has investors questioning if this is right time to sell.

The Organ Transport Devices Market is segmented by devices, disposables, perfusion solutions, and region from 2025 to 2035 ...